Keeping Abreast of the Development of Vaccines to Prevent COVID-19: What Clinicians Need to Know
Tweetorial #3 References

Tweet Three

Advisory Committee on Immunization Practices. ACIP evidence to recommendations for use of Pfizer-BioNTech COVID-19 vaccine under an emergency use authorization. CDC website. Reviewed December 17, 2020. Accessed April 14, 2021. https://www.cdc.gov/vaccines/acip/recs/grade/covid-19-pfizer-biontech-etr.html

Centers for Disease Control and Prevention. Science brief: emerging SARS-CoV-2 variants. CDC website. Updated January 28, 2021. Accessed April 14, 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html

Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. *N Engl J Med.* 2021;384(15):1466-1468. doi:10.1056/NEJMc2102017

Mahase E. COVID-19: where are we on vaccines and variants? *BMJ*. 2021;372:n597. doi:10.1136/bmj.n597

Moderna Inc. Moderna COVID-19 vaccine retains neutralizing activity against emerging variants first identified in the UK and the Republic of South Africa. Moderna website. January 25, 2021. Accessed April 14, 2021. https://investors.modernatx.com/news-releases/news-release-details/moderna-covid-19-vaccine-retains-neutralizing-activity-against

Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(50):1922-1924. doi:10.15585/mmwr.mm6950e2

Pfizer Inc. Pfizer and Biontech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study. Pfizer website. April 1, 2021. Accessed April 14, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious

Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *Nat Med*. Published online March 26, 2021. doi:10.1038/s41591-021-01318-5

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615. doi:10.1056/nejmoa2034577

Wang P, Wang M, Yu J, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. *bioRxiv.* Preprint posted online March 2, 2021. doi:10.1101/2021.03.01.433466

Tweet Four

Allergic reactions Including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(4):125-129. doi:10.15585/mmwr.mm7004e1

Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(2):46-51. doi:10.15585/mmwr.mm7002e1

Centers for Disease Control and Preventions. Interim clinical considerations for use of COVID-19 vaccines. CDC website. Updated May 14, 2021. Accessed May 20, 2021. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#Contraindications

Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021. *JAMA.* 2021;325(11):1101. doi:10.1001/jama.2021.1967

Tweet Six

MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients — United States, April 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(17):651-656. doi:10.15585/mmwr.mm7017e4

Tweet Seven

Shimabukuro TT. Thrombosis with thrombocytopenia syndrome (TTS) following Janssen COVID-19 vaccine. CDC website. April 23, 2021. Accessed May 23, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-04-23/03-COVID-Shimabukuro-508.pdf

Tweet Eight

Johnson & Johnson's Janssen COVID-19 Vaccine Overview and Safety. Centers for Disease Control and Prevention. Updated May 11, 2021. Accessed May 20, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html

MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients — United States, April 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(17):651-656. doi:10.15585/mmwr.mm7017e4

Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. *N Engl J Med*. 2021;384:1899-1909. doi:10.1056/nejmoa2103055

Tweet Nine

Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — eight U.S. locations, December 2020–March 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3

Tweet Ten

BioNTech SE. Study to evaluate the safety, tolerability, and immunogenicity of an RNA vaccine candidate against COVID-19 in healthy children <12 years of age. ClinicalTrials.gov website. Accessed May 20, 2021. https://clinicaltrials.gov/ct2/show/NCT04816643?term=covid%2Bvaccine%2Bpfizer%2Bkids&draw=2&rank=2

Food and Drug Administration. A study to evaluate the safety, reactogenicity, and coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. FDA website. May 10, 2021. Accessed May 23, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use

Moderna Inc. Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June. Moderna website. May 25 2021. Accessed May 25, 2021. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-teencove-study-its-covid-19-vaccine

ModernaTX, Inc. A study to evaluate safety and effectiveness of mRNA-1273 vaccine in healthy children between 6 months of age and less than 12 years of age. ClinicalTrials.gov website. Accessed May 20, 2021. https://clinicaltrials.gov/ct2/show/NCT04796896

ModernaTX, Inc. A study to evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 vaccine in adolescents 12 to <18 years old to prevent COVID-19. ClinicalTrials.gov website. Accessed May 20, 2021. https://clinicaltrials.gov/ct2/show/NCT04649151

Novavax, Inc. Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine. Novavax website. May 3 2021. Accessed May 25, 2021. https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-pediatric-expansion-phase-3-clinical-trial

Tweet Eleven

Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. *N Engl J Med*. 2021. doi:10.1056/nejmc2103916

Pfizer Inc. Pfizer and Biontech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study. Pfizer website. April 1, 2021. Accessed April 14, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious

Tweet Thirteen

Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nat Med.* 2021;27:790–792. https://doi.org/10.1038/s41591-021-01316-7

Tweet Fourteen

Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. *Sci Immunol.* 2021;6(58). doi:10.1126/sciimmunol.abi6950

Tweet Sixteen

Collier AY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. *JAMA*. Published online May 13, 2021. doi:10.1001/jama.2021.7563

Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. *Am J Obstet Gynecol*. 2021. doi:10.1016/j.ajog.2021.03.023

Tweet Seventeen

Khandekar A, O'Donell C. Novavax to start shipping COVID-19 vaccines to COVAX program in third quarter. Reuters website. Published May 6, 2021. Accessed May 20, 2021. https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-deliver-350-mln-covid-19-vaccine-doses-covax-scheme-2021-05-06/

Lovelace B Jr. Novavax expects FDA clearance for Covid vaccine as early as May, CEO says. CNBC website. Published March 1, 2021. Accessed May 20, 2021. https://www.cnbc.com/2021/03/01/covid-vaccine-novavax-expects-fda-clearance-for-covid-vaccine-as-early-as-may.html

Dyer O. Covid-19: US will send 60 million AstraZeneca doses abroad as domestic demand falls. *BMJ.* 2021;373. doi:10.1136/bmj.n1111

Tweet Eighteen

Novavax, Inc. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 trial. January 28, 2021. Accessed May 20, 2021. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3

Novavax, Inc. NVX-CoV2373 clinical update. Novavax website. September 2020. Accessed May 23, 2021. https://www.novavax.com/sites/default/files/2020-10/COVID-1_0.pdf

Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. *N Engl J Med*. 2021;384:1899-1909. doi:10.1056/nejmoa2103055

Tweet Nineteen

AstaZeneca. AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis. AstraZeneca website. March 2021. Accessed May 20, 2021. https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html

Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomized controlled trial. *Lancet.* 2021;397(10282):1351-1362. doi:10.1016/S0140-6736(21)00628-0

Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet.* 2020;396(10249):467-478. doi:10.1016/s0140-6736(20)31604-4

Madhi AS, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. *N Engl J Med.* 2021;384:1885-1898. doi:10.1056/NEJMoa2102214

Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet.* 2020;396(10267):1979-1993. doi:10.1016/s0140-6736(20)32466-1

Tweet Twenty

AstaZeneca. AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis. AstraZeneca website. March 2021. Accessed May 20, 2021. https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html

Reuters Staff. Factbox: Countries resume use of AstraZeneca vaccine, while some lose confidence. Reuters website. Published March 22, 2021. Accessed May 25, 2021. https://www.reuters.com/article/us-health-coronavirus-astrazeneca-vaccin/factbox-countries-resume-use-of-astrazeneca-vaccine-while-some-lose-confidence-idUSKBN2BE0V

Glossary

b/f, before
COVID-19, coronavirus disease 2019
CDC, Centers for Disease Control and Prevention
Ct, cycle threshold
CVST, cerebral venous sinus thrombosis
d, day(s)
EUA, emergency use authorization
FDA, Food and Drug Administration
HCP, healthcare provider
HIV, human immunodeficiency virus
HTN, hypertension
IgG, Immunoglobulin G
IM, intramuscular
m, month(s)
MMWR, Morbidity and Mortality Weekly Report
mRNA, messenger ribonucleic acid
NIH, National Institutes of Health
PBO, placebo
Ph, phase
RBD, receptor-binding domain
RCT, randomized controlled trial
RW, real-world
RWE, real-world evidence
SAE, serious adverse event
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
Temp, temporary
TTS, thrombosis with thrombocytopenia syndrome
Vax, vaccine
w, week(s)

w/, with
w/o, without
Y, year(s)
YO, years-old